Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2012 (2012), Article ID 412742, 5 pages
http://dx.doi.org/10.1155/2012/412742
Clinical Study

RIT with Y90-Ibritumomab Tiuxetan in Follicular Non-Hodgkin Lymphoma: Evaluation of Recent Outcomes in a Single Institution

1Department of Haematology, Miguel Servet University Hospital, Zaragoza, Spain
2Department of Nuclear Medicine, Miguel Servet University Hospital, Zaragoza, Spain
3Instituto Aragonés de Ciencias de la Salud (I+CS), Zaragoza, Spain
4Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER). Zaragoza, Spain

Received 3 March 2012; Revised 6 July 2012; Accepted 2 August 2012

Academic Editor: Paul G. Richardson

Copyright © 2012 Marcio Miguel Andrade Campos et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. Hiddemann, M. Kneba, M. Dreyling et al., “Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group,” Blood, vol. 106, no. 12, pp. 3725–3732, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. O. W. Press, “Radiolabeled antibody therapy of B-cell lymphomas,” Seminars in Oncology, vol. 26, no. 5, pp. 58–65, 1999. View at Google Scholar · View at Scopus
  3. T. Illidge and F. Morschhauser, “Radioimmunotherapy in follicular lymphoma,” Best Practice & Research, vol. 24, no. 2, pp. 279–293, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. T. E. Witzig, L. I. Gordon, F. Cabanillas et al., “Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma,” Journal of Clinical Oncology, vol. 20, no. 10, pp. 2453–2463, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. F. Morschhauser, J. Radford, A. van Hoof et al., “Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma,” Journal of Clinical Oncology, vol. 26, no. 32, pp. 5156–5164, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. F. Morschhauser, M. Dreyling, A. Rohatiner, F. Hagemeister, and A. Bischof Delaloye, “Rationale for consolidation to improve progression-free survival in patients with non-Hodgkin's lymphoma: a review of the evidence,” The Oncologist, vol. 14, supplement 2, pp. 17–29, 2009. View at Google Scholar · View at Scopus
  7. C. Emmanouilides, “Review of 90Y-ibritumomab tiuxetan as frist-line consolidation radio-immunotherapy for B-cell follicular non-Hodgkin’s lymphoma,” Cancer Management and Research, vol. 2, pp. 131–136, 2009. View at Google Scholar
  8. J. Hainsworth, D. Spigel, T. Markus et al., “Rituximab plus short-duration chemotherapy followed by Yttrium-90 ibritumomab tiuxetan as first-line treatment for patients with follicular non-hodgkin lymphoma: a phase II trial of the Sarah Cannon oncology research consortium,” Clinical Lymphoma & Myeloma, vol. 9, no. 3, pp. 223–228, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. L. I. Gordon, A. Molina, T. Witzig et al., “Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study,” Blood, vol. 103, no. 12, pp. 4429–4431, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. P. L. Zinzani, L. Gandolfi, V. Stefoni et al., “Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome,” Clinical Lymphoma, Myeloma and Leukemia, vol. 10, no. 4, pp. 258–261, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. T. M. Illidge, “Radioimmunotherapy of lymphoma: a treatment approach ahead of its time or past its sell-by date?” Journal of Clinical Oncology, vol. 28, no. 18, pp. 2944–2946, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. T. E. Witzig, C. A. White, G. A. Wiseman et al., “Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma,” Journal of Clinical Oncology, vol. 17, no. 12, pp. 3793–3803, 1999. View at Google Scholar · View at Scopus
  13. T. E. Witzig, A. Molina, L. I. Gordon et al., “Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan,” Cancer, vol. 109, no. 9, pp. 1804–1810, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. T. E. Witzig, I. W. Flinn, L. I. Gordon et al., “Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma,” Journal of Clinical Oncology, vol. 20, no. 15, pp. 3262–3269, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. O. Weigert, T. Illidge, W. Hiddemann, and M. Dreyling, “Recommendations for the use of Yttrium-90 ibritumomab tiuxetan in malignant lymphoma,” Cancer, vol. 107, no. 4, pp. 686–695, 2006. View at Publisher · View at Google Scholar · View at Scopus